Moderna: partnership for mRNA vaccines in Japan
(CercleFinance.com) - Moderna and Mitsubishi Tanabe Pharma Corporation have signed a partnership agreement to co-promote Moderna's mRNA respiratory vaccines in Japan, including the COVID-19 vaccine, Spikevax.
Moderna will be responsible for the manufacture, sale, medical education and distribution of its vaccines, while the two companies will work together to ensure broad access to these vaccines in Japan.
The agreement is valid until 31 March 2029. The management of both companies look forward to working together to improve public health in Japan.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Moderna will be responsible for the manufacture, sale, medical education and distribution of its vaccines, while the two companies will work together to ensure broad access to these vaccines in Japan.
The agreement is valid until 31 March 2029. The management of both companies look forward to working together to improve public health in Japan.
Copyright (c) 2024 CercleFinance.com. All rights reserved.